



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Whitty et al.

SERIAL NUMBER : 09/832,659

EXAMINER : Seharaseyon, J.

FILING DATE : April 11, 2001

ART UNIT : 1647

FOR : INTERFERON-BETA-1a - IMMUNOGLOBULIN FUSION PROTEINS AND
USES (as amended herein)

RECEIVED
15/a
M.9/J
4/2/03

Commissioner for Patents
Washington, D.C. 20231

APR 01 2003

AMENDMENT AND RESPONSE

TECH CENTER 1600/2900

This paper is in response to the December 3, 2002 Office Action ("Office Action"). With a one-month extension of time, these documents are due on or before April 3, 2003. Please charge any payments or credit any overpayments of the same to Deposit Account No. 50-0311, reference 00689-513 (A064).

Please amend the application as follows and consider the following remarks:

In the title:

Please replace the pending title with the following:

INTERFERON-BETA-1a - IMMUNOGLOBULIN FUSION PROTEINS AND USES

In the specification:

Please replace the paragraph beginning on page 4, line 28 with the following:

Figure 2. cDNA and deduced amino acid sequence for an interferon-beta-1a/Fc fusion. The full DNA and protein sequences of the human EFN-beta-1a/mouse Fc are shown in Figures 2A-1, 2A-2 and 2B. The human EFN-beta-1a protein sequences span amino acid residues 1-166 (DNA sequences 1-498). The enterokinase linker sequence spans amino acid residues 167-171 (DNA sequences 499-513). The murine IgG2a heavy chain protein sequence spans residues 172-399 (DNA sequences 514-1197).

Please replace the paragraph beginning on page 23, line 24 with the following:

Other derivatives of interferon beta/ Ig include covalent or aggregative conjugates of